Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosingSRP-5051 dosed monthly at 30...